A B S T R A C T Serum levels of immunoreactive insulinlike growth factors (IGF) I and II were determined by a modified IGF I and a new IGF II radioimmunoassay in normal children and adults, and in patients with acromegaly, isolated growth hormone deficiency, and extrapancreatic tumor hypoglycemia.
A B S T R A C T Serum levels of immunoreactive insulinlike growth factors (IGF) I and II were determined by a modified IGF I and a new IGF II radioimmunoassay in normal children and adults, and in patients with acromegaly, isolated growth hormone deficiency, and extrapancreatic tumor hypoglycemia.
Serum samples were gel filtered by a simple routine procedure at acidic pH to dissociate and separate IGF from the IGF carrier protein.
Mean immunoreactive IGF I levels (±SD; corrected for crossreactivity of IGF II) were 193+58 ng/ml in normal adult subjects, 712+245 ng/ml in acromegalic patients and 24±14 ng/ml in patients with isolated growth hormone deficiency. The lack of growth hormone alone, irrespective of an otherwise normal hormonal status, appears to be responsible for the drastic decrease of IGF I levels.
Oversecretion of growth hormone does not increase the levels of immunoreactive IGF II: mean levels (± SD; corrected for crossreactivity of IGF I) in normal and acromegalic subjects are virtually identical (647 ±126 and 641±189 ng/ml, respectively). Apparently, normal growth hormone levels stimulate IGF II production already maximally. However, in growth hormone deficiency immunoreactive IGF II is significantly decreased (252 ±99 ng/ml). Thus, IGF II, like IGF I, is growth hormone dependent. But in contrast to IGF I, the growth hormone dependence of IGF II seems to become apparent only at subnormal growth hormone levels.
In normal children IGF I is age dependent: it is low in newborn cord sera (51±20 ng/ml) and gradually rises into the adult range with increasing age. At the onset of and during puberty mean IGF I levels lie above prepubertal values. In contrast, IGF II levels in normal children are independent ofage and pubertal stage beyond the first year of life, whereas newborns have significantly lower IGF II values.
Hypoglycemia resulting from extrapancreatic tumors is not associated with increased immunoreactive IGF I or II levels. IGF I is decreased in most of the sera (mean level ±SD:56±39 ng/ml) whereas IGF II lies in INTRODUCTION The insulinlike growth factors (IGF) I and III are two polypeptides (7,500 mol wt) that have been isolated from human serum. They have been identified as homologues of the insulin molecule (1, 2) . However, they do not react with insulin antibodies (3) . Their biological effects tested so far are qualitatively identical to those of insulin (4) . They are also potent mitogens (4) and sulfation factors (4, 5) .
The immunoreactive (IR) IGF I levels in man depend on the growth hormone status (6) . IGF I can be classified as a somatomedin as originally defined by Daughaday et al. (7) . In addition, IGF I appears to be structurally similar-if not identical-to somatomedin C (8) (9) (10) (11) .
Although some indirect evidence for the growth hormone dependence of IGF II has been obtained recently (6) , conclusive evidence has been missing. It has now become possible to determine serum immunoreactive IGF II levels separately from those of regulation in different physiological and pathophysiological states. In this paper we describe a radioimmunoassay (RIA) for IGF-II and a modified IGF I RIA and their application in sera of normal subjects, patients with acromegaly and isolated growth hormone deficiency. In addition, we tried to answer the still pending question of whether or not extrapancreatic tumor hypoglycemia might be caused by elevated IGF levels. Despite the finding that total IGF as measured biologically and by competitive protein binding is not increased in these patients, and that IR-IGF I was found decreased rather than increased (6) , the possibility has not been excluded that this type of hypoglycemia may be associated with an elevation of IR-IGF II. 30 ,AI of sodiummetabisulfite (6 ,ug in 0.04 M phosphate buffer, pH 7.4). After addition of 250 IAI of 0.04 M phosphate buffer containing 2 g/100 ml of serum albumin the reaction mixture was immediately applied to a Sephadex G-50 medium column (2 x 33 cm), equilibrated with 0.1 M ammonium acetate containing 200 mg/100 ml of human serum albumin, and eluted with the same buffer (flow rate 27 ml/h). The peak of radioactivity eluting between 50 and 70% bed volume was collected and stored at -20°C. 70-90% of the radioactivity of this peak was precipitable by 10% trichloroacetic acid (TCA), depending on the time of storage. 65-85% of the TCA-precipitable counts were immunoprecipitable with the corresponding antiserum. The specific radioactivity of the tracer ranged between 40 and 80 sCi/A,g.
METHODS
Production of antisera. Antibodies against IGF I and II were raised in six and four mature rabbits, respectively. 400 ,ug of each of the pure polypeptides were dissolved in 270 ,ul of 0.005 N HCI. Then 230 ,ul of 1 M NaHCO3 were added followed by 500 IAI of 10% (wt/vol) KAI (25, 50 , and 100 ng) were added to 0.1 ml of phosphate-buffered saline/ 3% human serum albumin buffer (pH 7.4), gel filtered, and processed as described above, the total recovery by RIA was 74.0±3.6% (mean+SEM; n = 6). 63.0±3.2% was recovered in the 50-80%, and 11.0±2.0% in the 0-50% bed vol fraction. The recovery in the 50-80% fraction of unlabeled IGF I or II (25, 50 , and 100 ng) added to 0.1 ml of normal serum and chromatographed immediately was 66.0±2.7% (n = 6). 22 and 54 yr of age.
All acromegalic patients (22 females, 20 males, aged 27 to 65 yr) had elevated basal immunoreactive growth hormone levels (10->100 ng/ml) that were not suppressed below 6 ng/ml by an oral load of 100 g of glucose. 20 of these patients had already been included in an earlier study on immunoreactive IGF I levels, where a slightly different methodology both with regard to gel filtration and IGF I determination had been used (6) .
Sera from patients with isolated growth hormone deficiency (six males, six females; ages between 16 and 68 yr) were obtained from Dr. T. Merimee, Gainesville, Fla. The absence of growth hormone in these patients has been documented earlier (12, 13) . (14) .
Ofthe 22 patients with extrapancreatic tumor hypoglycemia (age between 13 and 85 yr; 8 females, 14 males), 8 had a fibrosarcoma, 2 a leiomyosarcoma, 3 a primary liver cell carcinoma, 1 a congenital mesoblastic nephroma, 1 a carcinoma of the stomach, 1 an undifferentiated carcinoma of the lungs, 1 a hemangioendothelioma, 1 a mesothelioma, 1 a carcinoma of the rectum (with liver metastases), 1 a benign fibroma of the lungs, 1 a fibroma of the pleura and 1 chronic myeloic leukemia. 10 of the patients had been included in an earlier study on IR-IGF levels (6) . Blood sugar values, at the time of blood sampling ranged between 20 and 45 mg/100 ml. IR insulin levels at this time were below 10 ,uU/ml.
RESULTS
Characteristics of the antiserum to IGF I and II. Antibodies against IGF I and II were detected after the second booster injection, i.e. around 5 wk after the first injection of each of the polypeptides. Two of the rabbits immunized with IGF II died during that time for unknown reasons. After the three following booster injections a further rise of the antibody titer was observed. Henceforth, the antibody titer remained constant. Antibody production in different animals varied greatly. The best two antisera against IGF I and II (1/118-101077, and II/12-8678) bound 50% of the TCA-precipitable counts (35-45% of totally added counts, depending on the time of storage of the tracers) at a final dilution of 1:1,500 and 1:2,000, respectively. Both antisera were used at a final dilution of 1:2,000 for the RIA. At this dilution specific binding (total binding minus binding in the presence of 50 ng/assay tube of the unlabeled polypeptide) of the IGF I and II antisera was 34 and 40%, respectively, of the added TCAprecipitable tracer (24-30 and 28-36% of the totally added counts, depending on the time of storage of the tracers).
Nonspecific binding in the presence of 50 ng per assay tube of unlabeled IGF I or II was 9.5 and 11%, respectively. These values are not significantly different from the binding of tracer in the absence of antiserum. The interassay variation for the IGF I and II RIA is +10.2 and ±10.9%, respectively (n = 20). Including the chromatographic step, the interassay variation is ± 14.8 and ± 11.2%, respectively (n = 20). The intraassay variation is ±2.35 and ±2.5% (n = 30). 1 ml of the IGF I antiserum bound 2.35 ug of IGF I (0.30 nmol), 1 ml of the IGF II antiserum 2.75 ,ug of IGF 11 (0.35 nmol). By using the above incubation procedure the sensitivity ofboth assays to pure IGF and stripped serum was increased twofold as compared with conditions where sample and tracer were added at the same time together with the antiserum.
Crossreactivities of IGF I, IGF II, SM-A, and SM-C in the IGF I and II RIA. As shown in Scatchard plots constructed from the competition curves of Fig. 1 are curvilinear (after subtraction of nonspecific binding in the presence of 50 ng of unlabeled hormone per tube). Thus, neither the IGF I nor the IGF II antiserum appears to contain a homogeneous population of antibodies. Fig. 1 shows also the crossreactivities of IGF I, IGF II, somatomedin A and somatomedin C in the two RIA. The crossreactivity of IGF II in the IGF I RIA is -1%, that of somatomedin A -10%, whereas somatomedin C behaves more or less identically to IGF I. In the IGF II RIA, IGF I, somatomedin A and somatomedin C all show a crossreactivity of -10%. With different dilutions of stripped serum the displacement curves are parallel to the standard curves in both RIA.
The following polypeptides did not crossreact in the IGF I RIA: somatomedin B and glucagon (up to 2.5 ,ug/ml), MSA-II, somatostatin, proinsulin, EGF and NSILP (up to 25 ug/ml), ACTH1_24, insulin, proinsulin-C-peptide, isolated insulin A-and B-chain, prolactin and HGH (up to 250 ,ug/ml). In the IGF II RIA no crossreactivity was observed with the following polypeptides: somatomedin B (up to 2.5 (Table I) , since the displacement curves with whole serum are not parallel to the standard curve (Fig. 2) . Surprisingly, the IGF II values determined in whole serum are in a similar range as those in stripped serum (Table I) , but again, the dilution curves are not parallel to the standard curve (Fig. 2) .
The interference with the IGF I and II RIA of IGF carrier protein in 0-50% bed vol fractions obtained after acidic gel filtration of several serum samples or in acid-lyophilized whole sera is demonstrated in Table II .
In six normal sera the IGF I and II RIA results obtained in the 50-80% bed vol fractions were 1.14+0.04 and 1.79+0.08-fold higher in the absence than in the presence of the 0-50% bed vol fraction. This ratio is different for sera from acromegalic patients: 0.82+0.02 for IGF I and 1.16 +0.06 for IGF II. For two sera from patients with extrapancreatic tumor hypoglycemia the factors were 1.5 for IGF I and 1.02 for IGF II. These relations are similar when the 50-80% bed vol fractions are compared with acid-lyophilized whole sera (Table  II) . Acid-ethanol extraction of the same serum samples FIGuRE 2 IGF I and II RIA carried out in whole serum of normal subjects, acromegalic, and hypopituitary patients. Incubations were carried out at 4°C as described in Methods. Antisera were used at a final dilution of 1:2,000. All points represent the means of duplicates (intraassay variation±2.35 and ±2.5% for the IGF I and II RIA, respectively). As in Fig. 1 I and II levels obtained in normal, acromegalic, and growth-hormone deficient patients. After correction for crossreacting IGF II in the IGF I-RIA (-1%; Fig. 1 ), the mean IGF I level in normal subjects is 193+58 (SD) ng/ml; in acromegalic patients it is 712+245 ng/ ml and in growth-hormone deficient patients it is 24+14 ng/ml. After correction for crossreacting IGF I in the IGF II-RIA (-10%, Fig. 1 ), mean IGF II levels are 647+126 (SD) ng/ml in normal adult subjects, 641+189 ng/ml in acromegalic patients, and 252±99 ng/ml in patients with isolated growth hormone deficiency. Thus, IGF II levels are not significantly different in normal and acromegalic patients (P > 0.1), whereas they are significantly below normal in the dwarf group (P < 0.01). IGF I levels in children are age-dependent (Fig.  4) . They lie significantly below the adult level in newborn cord sera and in children below 6 yr of age. After 1 yr of age there is a gradual rise of the mean IGF I level. With the onset of puberty IGF I rises above the normal adult level. The increase seems to occur earlier in girls than in boys. At that time most of the IGF I levels reach values close to or even within the range observed in adult acromegalic patients. This pattern is completely different for IGF II (Fig. 5) normal range. IR-IGF II varied from 340 to 1,000 ng/ ml. Its mean level (556±195 ng/ml) was statistically not significantly different from normal and remained unchanged after operation.
DISCUSSION
One of the problems encountered in the determination of IR-IGF in serum is caused by the tight association of IGF I and II with specific carrier protein(s) (16) . The apparent affinities of IGF I and II toward the carrier protein(s) (-1.6 and -1.2 nM, respectively) (4) lie in an order of magnitude similar to the concentrations that cause half-maximal displacement in the RIA competition curves of Fig. 1 (-0.23 and -0.37 nM). Since the carrier protein(s) in native serum is only partially saturated with IGF (17) the RIA in whole serum constitutes a complex multicomponent system. In this system the tracer may not only compete with the unlabeled native IGF-carrier complex for binding to the antibodies (Results), but may also bind to nonsaturated carrier protein(s). The resulting labeled IGFcarrier complex may then also compete with the free tracer and with the unlabeled carrier complex for the antibodies. One might expect that the unsaturated carrier protein, the amount of which is unknown and which may vary in different physiological and pathophysiological states, would influence the results of the RIA. Therefore, we do not carry out the IGF-RIA in whole serum. Even incubation under disequilibrium conditions does not help to solve the problem (Fig.  2) . The values obtained for IGF I in whole serum are two-to threefold lower (depending on the serum dilution) than those obtained after dissociation and separation of IGF from the carrier protein(s) ( Table I ). The same observation has been made by Daughaday et al. (15) . These authors extracted their serum samples with acid-ethanol, which dissociates the IGF-carrier complex and apparently removes the carrier protein. After acid-ethanol extraction they found IGF I values, determined by radioreceptor assay, and somatomedin C (SM-C) values measured by RIA, to lie 2.7-and 3-fold higher than in the unextracted whole normal serum (15) . They concluded from these results that the failure of quantitative recovery in whole serum may be due to "modification by steric and other factors of access of the somatomedin serum binding protein complex to membrane and immunobinding sites." Our IGF I RIA results in whole and gel filtered sera (Table  I) would also be interpretable along this line. The IGF-RIA introduced by Reber and Liske (18) was carried out in whole serum under equilibrium conditions. Therefore, the results are difficult to interpret. Furlanetto et al. (19) originally measured SM-C in whole serum under disequilibrium conditions. They now report that this procedure may underestimate SM-C (20 (Table II) .
The finding that after gel filtration immunoreactive serum IGF levels are lower than after acid-ethanol extraction of sera would be consistent with losses of IGF during the former procedure. This is indicated by the results of the recovery of exogenous IGF added to serum or albumin-buffer (Methods). The total recovery by the gel filtration method is -74%, whereas Daughaday et al. (15) report a recovery of 100%. -10% of the IGF is "lost" in the 0-50% bed vol fraction on gel filtration, and 63-66% are recovered in the 50-80% pool. Based on the assumption that the recovery of exogenous is identical to that of endogenous IGF, all serum levels reported in this study would have to be multiplied by a factor of 1.5. Hall et al. (22) perform their SM-A RIA in whole serum using Sepharose-bound antibodies against SM-A and a 6-d incubation under disequilibrium conditions. Since in their RIA IGF I is -10 times more potent than SM-A itself their SM-A levels in normal subjects (-1,000 ng/ml) would correspond to -100 nglml of IGF I. This is close to the level of IGF I that we find in normal whole serum at a 1:10 dilution (Fig. 2) .
The methodology presently used for the determination of IR-IGF I differs from the previous one (6) in the following respects: (a) a new IGF I antiserum is used: (b) the smaller size of the columns and the simplified gel filtration procedure now allow to process small amounts of serum (100 ,ul) and a reasonable number of serum samples (at least 20/day); (c) samples are now preincubated with the antiserum for 24 h before the tracer is added and incubation is continued for another 24 h; under these conditions the sensitivity of the assay is increased; (d) separation of the IGFantibody complex is performed by the double antibody technique instead of the charcoal separation.
Despite these modifications the results obtained in this study for the mean IGF I levels in normal, acro-megalic, and hypopituitary subjects are close to those reported earlier. The results confirm our previous data on the GH-dependence ofIR-IGF I levels as well as the data of others on the GH-dependence of IR-SM-C (19, 23), IR-SM-A (22) and of a SM-C-like polypeptide (20) . In addition, the investigation in patients with isolated GH deficiency demonstrates that the lack of GH alone, irrespective of an otherwise normal hormonal status, is responsible for the drastic decrease of IR-IGF I in serum.
One of the results that differs from the earlier report (6) is the crossreactivity of SM-A in the IGF I RIA. It is 10% with the new antiserum, but was identical to IGF I with the antiserum used before (kindly supplied by Dr. Reber, Hoffmann-La Roche, Basel, Switzerland). The finding with the new antiserum agrees with that of Hall et al. (22) , who reported that SM-A was 10% as potent as IGF I in their SM-A RIA (22) . Thus, our new IGF I antiserum discriminates better between IGF I and SM-A.
The dependence of IGF I on age and its increase during puberty has also been reported by Hall et al. (24) for SM-A and by Bala et al. for a basic somatomedin (25) , which is similar to SM-C/IGF I. In children below the age of 10 yr it may be difficult to diagnose growth hormone deficiency on the basis of IR-IGF I: serum levels may lie within or close to the hypopituitary range. Measurement of IGF II in these situations, however, allows to distinguish between the normal and GH deficient state, since IGF II is significantly decreased in GH-deficient children (Zapf, J., unpublished observations).
The discrepancy between the high growth rate of newborns and their low IGF I and II levels is at first sight striking and appears to be at variance with the concept that somatomedins are GH-dependent stimulators of skeletal growth. However, any such conclusion would be invalid and meaningless as long as the mechanism of action of SM in vivo, the physiological role of the carrier protein and the sensitivity towards SM of tissues at various stages of development have not been disclosed. By the same token, it would be premature to conclude that the pubertal growth spurt is causally related to elevated IGF I levels.
The Fig. 6 ), IGF II has been found to lie within the normal range (Fig. 6 ). The mode of regulation of IGF II is not yet known. Hypoglycemia in patients with extrapancreatic tumors has been attributed to an elevation of IGF (28, 29) . In such patients we have found earlier that total IGF levels (as determined biologically and by the protein binding assay) are either normal or slightly decreased (6) . IR-IGF I levels in this earlier study were found to be significantly decreased in 5 of 10 patients (6) . These findings together with our present results obtained for IR-IGF I and II in these patients speak against a causal relationship between IGF and this type of hypoglycemia. It is also unlikely that the increased ratio of IGF and IGF carrier protein (6) is responsible for the sustained hypoglycemia in these patients, since this ratio is decreased in acromegalics as well (6) . Most acromegalics display some degree of glucose intolerance and hyperglycemia rather than hypoglycemia.
The discrepancy between our results and those of Megyesi et al. and Hyodo et al. (28, 29) is most likely due to methodological differences in the determination of IGF. Megyesi et al. measured IGF by a rat liver membrane radioreceptor assay. In some of the studies of these authors the partially purified IGF tracer (which contained both IGF I and II) was replaced by labeled MSA. Lately, Rechler et al. (30) have shown that IGF II and MSA behave similarly with respect to binding to rat liver membranes, whereas IGF I binds only poorly in this system and displaces 125I-IGF II with a potency of only -2% ofthat of IGF II. Therefore, Megyesi et al. (28) measured IGF II or a related factor rather than IGF I in their radioreceptor assay. This would also explain that they found normal IGF levels in acromegalic patients (31) . IR-IGF II levels in acromegaly are in fact the same as in normal subjects (Fig. 3) .
The increase in receptor-reactive material found by Megyesi et al. and by Hyodo et al. (28, 29) is unlikely to be attributable to an increase in IR-IGF II, which we do not find elevated in our tumor patients. Surprisingly, Daughaday et al. (26) recently reported that IGF II levels were elevated in five of six patients with nonislet cell tumors in the rat placental membrane RRA. All these findings would support the hypothesis that sera of patients with extrapancreatic tumor hypoglycemia may contain substances that crossreact with IGF II at the IGF II receptor of rat liver and rat placental membranes. Apparently, these substances do not crossreact at the insulin receptor of adipose tissue, since biologically active IGF in these sera, as tested in the fat pad or fat cell assay, is not elevated (6) .
Further studies on the function of this unique IGF II receptor of liver and placental membranes are required before one can speculate about the role of such IGF II-like substances in the pathogenesis of tumor hypoglycemia.
